TickerTain — Make Analysis Fun Again

←

▶ 18:51 · $STEALTH-BIOSCIENCES · Stealth Biosciences owns SS31 mitochondrial peptide, enforcing IP against unauthorized sellers

now playing · $STEALTH-BIOSCIENCES

$SUPERPOWERbullish· high· posmax marchione

Superpower raises $40M Series A, growing thousands of members/month with AI-first health platform

Superpower builds AI-first health platform with 100+ biomarker testing ($199), digital twin, AI clinical reasoning (ensemble models + proprietary clinical canon), and action layer…

$HIMS···neutral· highmax marchione

Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach

Hims follows a CPG/e-commerce path (fastest to revenue/gross profit) but lacks lifestyle brand and tech layer; Superpower takes product-first tech approach with stronger retention…

$NVO···neutral· highmax marchione

Novo Nordisk and Eli Lilly will own future patented GLP-1 classes, making compounding risky long-term

Future GLP-1 generations will be patented by Eli Lilly and Novo Nordisk with defensible IP, making current compounding bets risky long-term despite short-term viability. The next…

$STEALTH-BIOSCIENCESneutral· lowmax marchione

Stealth Biosciences owns SS31 mitochondrial peptide, enforcing IP against unauthorized sellers

Stealth Biosciences holds IP on SS31 (mitochondrial peptide for longevity/energy) and actively sends cease-and-desist letters to unauthorized sellers, indicating defensible patent…

$OPENAIneutral· highmax marchione

ChatGPT Health is a 'nothing burger' but ChatGPT remains formidable as potential health demand aggregator

ChatGPT Health launch adds nothing new (just a tab) since ChatGPT already captures health queries, wants user context, and moves into action layer. However, ChatGPT could become t…

$LLY···bullish· mediummax marchione

Eli Lilly potentially undervalued but needs Pharma 2.0 transformation to own patient relationship

Eli Lilly could be underpriced despite trillion-dollar valuation, but must transition from Pharma 1.0 (disease drugs via payers/health systems) to Pharma 2.0 (wellness drugs direc…

←